We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Infra-Red Technology Based Test Can Rapidly Predict Severe COVID-19

By LabMedica International staff writers
Posted on 18 Aug 2021
Scientists have developed a way of using infra-red technology to rapidly test which patients are most at risk of becoming severely unwell from COVID-19.

In a small pilot study of COVID-19 patients in India that led by QIMR Berghofer Medical Research Institute (Brisbane, Australia) and the Indian Institute of Technology (Maharashtra, India), the test performed with 85% accuracy. More...
The researchers hope that the test could in future be used to triage patients in areas with large outbreaks of the disease.

The test was developed through an international collaboration between academia and industry using blood samples from 128 COVID-19 patients in Mumbai, India. Infra-red spectra measure the levels of different chemical groups in a sample. The team then used artificial intelligence to develop an algorithm to work out which chemical groups, or ‘signatures’, were correlated with patients who became severely unwell.

“We found there were measurable differences in the infra-red spectra in the patients who became severely unwell. In particular, there were differences in two infra-red regions that correspond to sugar and phosphate chemical groups, as well as primary amines, which occur in specific types of proteins,” said Associate Professor Michelle Hill, head of QIMR Berghofer’s Precision and Systems Biomedicine Research Group.

“We also found that having diabetes was a predictor of becoming severely unwell in this group of patients, so we fed this information into the algorithm. We then tested the algorithm on blood samples from a separate group of 30 patients from Mumbai and found it was 85 per cent accurate in predicting which patients would become severely ill,” Associate Professor Hill said. “However, it did result in more ‘false positives’ than predictions that were based solely on the clinical risk factors of age, sex, hypertension and diabetes. We hope that with more testing we can reduce these false positives.”

“From our study, we can say that there is a correlation between blood chemical signature and becoming severely unwell with COVID-19,” said Professor Sanjeeva Srivastava, head of the Proteomics Facility at the Indian Institute of Technology. She added that the finding that there were chemical differences in more severe COVID-19 cases was consistent with published studies conducted in other countries.

Related Links:
QIMR Berghofer Medical Research Institute
Indian Institute of Technology



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Electrolyte Analyzer
BKE-B
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.